Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06610201 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Bleeding and Treatment in Participants With Von Willebrand Disease

StatusRecruiting
PhaseNot specified
SponsorHemab ApS
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion pushed from Jun 2026 to Dec 2026
    • Eligibility criteria expanded, about 200 words
    • Secondary endpoints: details revised at 1 of 6 entries
    • Site details revised at 1 of 17 sites
    v10
  2. Site details revised at 1 of 17 sitesv9
  3. Site details revised at 1 of 17 sitesv8
  4. Study sites: 15 to 17v7
  5. Re-verified, no change to tracked fieldsv6
Show 4 earlier versionsHide 4 earlier versions
  1. Primary and study completion dates: Feb 2026 to Jun 2026v5 Show 6 more changesShow less
    • Interventions: Clinical outcomes of patients with VWD, Type 1 (less than 40 IU per dL) (Other), Clinical outcomes of patients with VWD, Type 1 (less than… to Clinical outcomes of patients with VWD, Type 1 (Other), Clinical outcomes of patients with VWD, Type 2A, Type 2M, Type 2N, or Type 3 (Other)
    • Eligibility criteria shortened, about 172 words
    • Secondary endpoints: 5 to 6
    • Study description shortened, about 63 words
    • Site details revised at 15 of 15 sites
    • Study arms: 3 to 2
  2. Study sites: 1 to 15
    • Collaborators shortened, about 2 words
    v4
  3. Interventions: Clinical outcomes of patients with VWD, Type 1 (less than 30 IU per dL) (Other), Clinical outcomes of patients with VWD, Type 1 (less than… to Clinical outcomes of patients with VWD, Type 1 (less than 40 IU per dL) (Other), Clinical outcomes of patients with VWD, Type 1 (less than…
    • Eligibility criteria revised
    • Study description revised
    v3
  4. Study title shortened, about 2 wordsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Hemab ApS
5 trials monitored
See 1 trial at risk
The purpose of this screening study is to accumulate information regarding bleeding events, quality of life, and the social and clinical impact of bleeds in participants with Von Willebrand Disease (VWD). Data from this study will be used to establish baseline bleeding and treatment rates in a population of participants with VWD and act as comparator data for future clinical study outcomes.(e.g. Velora Pioneer)
Trial Details
NCT Number NCT06610201
Lead Sponsor Hemab ApS
Conditions
(from sponsor)		 Von Willebrand Disease (VWD), Von Willebrand Disease (VWD), Type 1, Von Willebrand Disease (VWD), Type 2, Von Willebrand Disease (VWD), Type 3, Von Willebrand Disease, Type 2A, Von Willebrand Disease, Type 2M, Von Willebrand Disease, Type 2N
Related terms von Willebrand Disease, Type 2, von Willebrand Disease, Type 3, von Willebrand Diseases
Enrollment 200 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov